spacer
home > epc > spring 2017 > getting interactive
PUBLICATIONS
European Pharmaceutical Contractor

Getting Interactive

The pharmaceutical market is booming, evidenced by revenue numbers which exceeded the $1 trillion milestone in 2015, as noted in the International Trade Commission’s 2016 Top Markets Report on Pharmaceuticals (1). A good portion of that is invested in research, so there are a lot of promising developments happening in the clinical trial space. Despite these advancements, however, many industry investments in research are wasted due to problems with clinical supply management.

To get to the heart of the issue, 200 studies that wrapped up over the past two years have recently been reviewed. Out of them, 62% of the material packaged and released was not even used – two thirds of supplies never actually made it to a patient, meaning there was unnecessary spending.

Assessing the Costs

What makes up the costs associated with clinical supplies? One of the biggest considerations is drug expenses, which includes everything from production to packaging and storage. For these factors, there are fixed and variable costs that must be closely examined – for example, if a trial has 1,000 patients getting three kits each, 3,000 kits must be produced. It is also important to create an overage as it is impossible to know where those patients are going to be at all times. Buffers are also necessary and it is vital to ensure that sites do not run out of drugs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stefan Dürr has been working with interactive response technologies for 12 years and is currently Senior Director of Project Management at Cenduit. He is responsible for global project management and support services groups at the company with teams in India, Japan, Switzerland and the US. Stefan holds a Master’s of Science in Molecular Biology and is passionate about finding innovative solutions for clinical supply challenges.
spacer
Stefan Dürr
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

5th Annual Peptides Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our highly anticipated 5th Annual Peptides Congress, 16th– 17th April 2018, London, UK. Over 450 peptides, proteins and antibodies attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement